Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.

Hoth will form and operate a new wholly owned subsidiary named Merveille.ai, which will focus on screening for collaborative opportunities utilizing Artificial Intelligence in the field of drug discovery.

Robb Knie, Chief Executive Officer of Hoth, stated, "We believe our current pipeline might have new unscreened opportunities to help patients dealing with rare diseases. We hope to utilize AI to further enhance our pipeline and partnering opportunities."

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/. 

Investor Contact:

LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

SOURCE Hoth Therapeutics, Inc.

Report Abuse